Treat-to-target in rheumatoid arthritis: Clinical and pharmacoeconomic considerations

Ariel Beresniak, Jürgen Braun, Paolo Cortesi, Gianfranco Ferraccioli, Merete Lund Hetland, Johannes W G Jacobs, Arthur Kavanaugh, Raashid Luqmani, Marta Mosca, Theodore Pincus, Duncan Porter, Vappu Rantalaiho, Angelo Ravelli, David L. Scott, Josef Smolen, Christian Thielscher, Giuseppe Turchetti, Marianne Van Den Broek, Yusuf Yazici

Research output: Contribution to journalArticle

Original languageEnglish
JournalClinical and Experimental Rheumatology
Volume30
Issue number4 SUPPL.73
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Beresniak, A., Braun, J., Cortesi, P., Ferraccioli, G., Hetland, M. L., Jacobs, J. W. G., Kavanaugh, A., Luqmani, R., Mosca, M., Pincus, T., Porter, D., Rantalaiho, V., Ravelli, A., Scott, D. L., Smolen, J., Thielscher, C., Turchetti, G., Van Den Broek, M., & Yazici, Y. (2012). Treat-to-target in rheumatoid arthritis: Clinical and pharmacoeconomic considerations. Clinical and Experimental Rheumatology, 30(4 SUPPL.73).